Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Cystic Fibrosis Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Cystic Fibrosis Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Cystic Fibrosis Pipeline Drugs Assessment

 

Overview:

Cystic fibrosis is a inherited disease, enables damage lungs, gastro-intestinal tract and other parts of the body. Cystic fibrosis occur due to defective gene and affects the secreting cells of the body and causes thickening of the body fluids such as muscus, sweat and digestive juices. These body fluids plung up the ducts, tubes and passages, especially in lungs and pancreas.

Cystic Fibriosis signs and syptoms develops along with the severity of the disease. Patients may have excess of salt content in sweat than normal and reoccurs pneumonia. Diagnostictests include sweat tests and genetic tests. There is no cure for the disease. Medications are used to treat the disease and reduce the symptoms. Medications may include, mucus thinning agents, antibiotics, anti inflamatory, inhalation brancodialators and others.

 

Segmentation:

By route of administration, cystic fibrosis pipeline drugs are segmented into

  • Oral
  • Inhalations
  • Parenteral
  • Others

By therapeutic approach, cystic fibrosis pipeline drugs are segmented into

  • CFTR Function Restoring
  • Mucociliary Clearance
  • Anti-Infective
  • Others

By trial phase, Cystic Fibrosis pipeline drugs are segmented into

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By company, Cystic Fibrosis pipeline drugs are segmented into

  • Novartis AG (Switzerland)
  • Galapagos NV (Belgium)
  • Vertex Pharmaceuticals (U.S.)
  • Proteostasis Therapeutics Inc. (U.S.)
  • ProQR Therapeutics (Netherlands)
  • AstraZeneca plc. (UK)
  • Spyryx Biosciences (U.S.)
  • Alaxia (France)
  • Sound Pharmaceuticals Inc. (U.S.)
  • Laurent Pharmaceuticals (Canada)

 

Space Analysis:

Majority of the drugs under the development for the treatment of the cystic fibrosis are funded by the non-government and government organizations to improve the treatment options. Majority of the companies focusing on development of drugs that restore the CFTR gene function and rest of the therapeutic approaches include Mucociliary Clearance, Nutritional-GI, anti-infective agents and others

  • In October 2016, Celtaxsys announced publication of results demonstrating safety, tolerability and pharmacokinetic & dynamic profile of novel anti-inflammatory medicine, Acebilustat, in phase I trials including CF patients.

 

Report Description:

Cystic Fibrosis Pipeline Drugs Assessment report studies the various therapeutics under clinical development for cystic fibrosistreatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Cystic Fibrosis pipeline drugsdevelopment. This report studies the dynamics of the Cystic Fibrosis Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Cystic Fibrosis pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis onthe each drug candidates in the clinical trial phases

 

  1. Executive Summary
  2. Global Cystic Fibrosis Pipeline Drugs Assessment Market Introduction
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market – Taxonomy
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market –Definitions
      • Route of Administration
      • Therapeutic Approach
      • Trial Phase
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market – Competition Landscape
    • Epidemiology
  2. Global Cystic Fibrosis Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Cystic Fibrosis Pipeline Drugs Assessment Market, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Inhalations
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Forecast, By Therapeutic Approach,2013 – 2017 and Forecast, 2018 – 2024
    • CFTR Function Restoring
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Mucociliary Clearance
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-Infective
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Phase I
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase II
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase III
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase IV
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Region, 2018 – 2024
  2. North America Cystic Fibrosis Pipeline Drugs Assessment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Cystic Fibrosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • North America Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  3. Europe Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Cystic Fibrosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • Europe Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  4. Asia-Pacific Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Cystic Fibrosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • Asia-Pacific Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  5. Latin America Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Cystic Fibrosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • Latin America Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  6. Middle East and Africa Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Cystic Fibrosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • MEA Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Novartis AG (Switzerland)
      • Galapagos NV (Belgium)
      • Vertex Pharmaceuticals (U.S.)
      • Proteostasis Therapeutics Inc. (U.S.)
      • ProQR Therapeutics (Netherlands)
      • AstraZeneca plc. (UK)
      • Spyryx Biosciences (U.S.)
      • Alaxia (France)
      • Sound Pharmaceuticals Inc. (U.S.)
      • Laurent Pharmaceuticals (Canada)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Disclaimer

The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553